<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00453206</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00001366</org_study_id>
    <secondary_id>CCCWFU-29506</secondary_id>
    <secondary_id>IRB00001366</secondary_id>
    <nct_id>NCT00453206</nct_id>
  </id_info>
  <brief_title>Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases</brief_title>
  <official_title>Reduced Intensity Allogeneic Hematopoietic Cell Transplantation for Patients With Hematological Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving chemotherapy, such as fludarabine, busulfan, and melphalan, before a donor&#xD;
      peripheral stem cell transplant or bone marrow transplant helps stop the growth of cancer or&#xD;
      abnormal cells. It also helps stop the patient's immune system from rejecting the donor's&#xD;
      stem cells. When the healthy stem cells from a donor are infused into the patient they may&#xD;
      help the patient's bone marrow make stem cells, red blood cells, white blood cells, and&#xD;
      platelets. Sometimes the transplanted cells from a donor can make an immune response against&#xD;
      the body's normal cells. Giving tacrolimus, methotrexate, mycophenolate mofetil, and&#xD;
      antithymocyte globulin before and after transplant may stop this from happening. Once the&#xD;
      donated stem cells begin working, the patient's immune system may see the remaining cancer or&#xD;
      abnormal cells as not belonging in the patient's body and destroy them (graft-versus-tumor&#xD;
      effect). Giving an infusion of the donor's white blood cells (donor lymphocyte infusion) may&#xD;
      boost this effect.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well donor stem cell transplant works in&#xD;
      treating patients with hematologic cancer or other diseases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the feasibility (i.e., risk of treatment-related mortality during the first 6&#xD;
           months after transplantation) of administering reduced-intensity allogeneic&#xD;
           hematopoietic stem cell transplantation to patients with hematologic cancer or other&#xD;
           diseases.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the response rate (partial and complete response), 6- and 12-month&#xD;
           probabilities of response, and time to progression in patients treated with this&#xD;
           regimen.&#xD;
&#xD;
        -  Determine the risk of acute and chronic graft-versus-host disease in patients treated&#xD;
           with this regimen.&#xD;
&#xD;
        -  Determine other toxicities of this regimen in these patients.&#xD;
&#xD;
        -  Determine the overall survival and disease-free survival of patients treated with this&#xD;
           regimen.&#xD;
&#xD;
        -  Determine the impact of iron status on overall and disease-free survival.&#xD;
&#xD;
        -  Determine the influence of quality of life (at time of transplantation) on overall&#xD;
           survival.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
        -  Preparative regimen: Patients receive fludarabine phosphate IV over 30 minutes on days&#xD;
           -7 to -3. Patients also receive busulfan IV over 2 hours every 6 hours on days -4 and -3&#xD;
           or melphalan IV over 2 hours on day -3.&#xD;
&#xD;
        -  Graft-versus-host disease (GVHD) prophylaxis: Patients with matched related donors&#xD;
           receive oral tacrolimus twice daily on days -1 to 90 followed by a taper until day 180.&#xD;
           Patients also receive methotrexate IV on days 1, 3, and 6. Patients with matched&#xD;
           unrelated and 9/10 matched related donors receive oral tacrolimus twice daily on days -1&#xD;
           to 180 followed by a taper; methotrexate IV on days 1, 3, 6, and 11; and oral&#xD;
           mycophenolate mofetil twice daily on days -2 to 60 followed by a taper. All patients&#xD;
           also receive antithymocyte globulin IV over 4 to 6 hours once a day on days -4 to -1.&#xD;
&#xD;
        -  Allogeneic stem cell transplantation: Patients undergo allogeneic peripheral blood stem&#xD;
           cell transplantation or bone marrow transplantation on day 0. Patients receive&#xD;
           filgrastim (G-CSF) beginning on day 7 and continuing until blood counts recover.&#xD;
&#xD;
        -  Lymphocyte infusion: Patients with progressive or stable disease while off&#xD;
           immunosuppression and no active GVHD may receive up to 3 donor lymphocyte infusions from&#xD;
           the original donor at 8-week intervals beginning on day 180 or 210 .&#xD;
&#xD;
      Quality of life is assessed at baseline.&#xD;
&#xD;
      After completion of study therapy, patients are followed every 3 months for 2 years and then&#xD;
      every 6 months for up to 3 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment-related Mortality Within the First 6 Months After Transplantation</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Response</measure>
    <time_frame>monthly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>monthly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free Survival</measure>
    <time_frame>monthly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft-versus-host Disease</measure>
    <time_frame>monthly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Iron Status at the Time of Transplantation</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life at the Time of Transplantation</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related Mortality at 100 Days After Transplantation</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">66</enrollment>
  <condition>Chronic Myeloproliferative Disorders</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic hematopoietic stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>nonmyeloablative allogeneic hematopoietic stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed hematological disease, including any of the following:&#xD;
&#xD;
               -  Chronic lymphocytic leukemia&#xD;
&#xD;
                    -  Absolute lymphocytosis &gt; 5,000/µL&#xD;
&#xD;
                    -  Morphologically mature lymphocytes with &lt; 55% prolymphocytes&#xD;
&#xD;
                    -  Lymphocyte phenotype with expression of CD19 and CD5&#xD;
&#xD;
                    -  Absence of CD23 expression allowed provided disease is morphologically&#xD;
                       distinguished from mantle cell lymphoma&#xD;
&#xD;
               -  Prolymphocytic leukemia&#xD;
&#xD;
                    -  Absolute lymphocytosis &gt; 5,000/µL&#xD;
&#xD;
                    -  Morphologically mature lymphocytes with &gt; 55% prolymphocytes&#xD;
&#xD;
               -  Non-Hodgkin's or Hodgkin's lymphoma&#xD;
&#xD;
                    -  Any WHO classification histologic subtype&#xD;
&#xD;
                    -  Diagnosis by core biopsy allowed provided there is adequate tissue for&#xD;
                       diagnosis and immunophenotyping&#xD;
&#xD;
                    -  Diagnosis by bone marrow biopsy not acceptable for follicular lymphomas&#xD;
&#xD;
               -  Multiple myeloma&#xD;
&#xD;
                    -  Has received ≥ 1 prior treatment regimen&#xD;
&#xD;
                    -  Has a partial response or greater by the Blade Criteria&#xD;
&#xD;
                    -  Patients who achieved complete remission are eligible&#xD;
&#xD;
               -  Acute myeloid leukemia&#xD;
&#xD;
                    -  Documented control (i.e., &lt; 10% bone marrow blasts and no circulating&#xD;
                       blasts)&#xD;
&#xD;
               -  Myelodysplastic syndromes&#xD;
&#xD;
                    -  Documented disease as defined by WHO or French-American-British Cooperative&#xD;
                       group criteria&#xD;
&#xD;
                    -  Chronic myelogenous leukemia&#xD;
&#xD;
               -  Patients with atypical chronic myelogenous leukemia (i.e., absent Philadelphia&#xD;
                  chromosome) are eligible&#xD;
&#xD;
               -  Polycythemia vera&#xD;
&#xD;
                    -  Documented disease as defined by WHO criteria (i.e., A1 + A2, and any other&#xD;
                       category A, OR A1 + A2, and any 2 category B):&#xD;
&#xD;
                         -  A1: Total red blood cell mass &gt; 25% above mean normal predicted value&#xD;
                            OR hemoglobin &gt; 18.5 g/dL in males, 16.5 g/dL in females (hematocrit ≥&#xD;
                            60% in males or ≥ 56% in females)&#xD;
&#xD;
                         -  A2: No cause of secondary erythrocytosis (absence of familial&#xD;
                            erythrocytosis, no elevation of epoetin alfa [EPO] due to hypoxia, high&#xD;
                            oxygen affinity hemoglobin, truncated EPO receptor, or inappropriate&#xD;
                            ectopic EPO production)&#xD;
&#xD;
                         -  A3: Splenomegaly&#xD;
&#xD;
                         -  A4: Clonal genetic abnormality other than the Philadelphia chromosome&#xD;
&#xD;
                         -  A5: Endogenous erythroid colony formation in vitro&#xD;
&#xD;
                         -  B: Platelet count &gt; 400,000/mm³, WBC &gt; 12,000/mm³, bone marrow biopsy&#xD;
                            with prominent erythroid and megakaryocytic proliferation, and low&#xD;
                            serum EPO&#xD;
&#xD;
               -  Chronic idiopathic myelofibrosis&#xD;
&#xD;
                    -  Documented disease as defined by WHO criteria&#xD;
&#xD;
                    -  Must have a HLA-identical donor, a matched unrelated donor, or a HLA 9/10&#xD;
                       related donor meeting the following criteria:&#xD;
&#xD;
                    -  HLA-identical sibling (6/6)&#xD;
&#xD;
                         -  Serologic typing for class I (A, B)&#xD;
&#xD;
                         -  Molecular typing for class II (DRB1)&#xD;
&#xD;
                    -  9/10 matched related donor&#xD;
&#xD;
                         -  High-resolution molecular typing at HLA-A, B, C, DRB1, and DQB1&#xD;
&#xD;
                         -  Only a single mismatch at one class I or II allele allowed&#xD;
&#xD;
                    -  10/10 matched unrelated donor&#xD;
&#xD;
                         -  Molecular identity at HLA-A, B, C, DRB1, and DQB1 by high-resolution&#xD;
                            typing&#xD;
&#xD;
                         -  Syngeneic donors are not eligible&#xD;
&#xD;
          -  Creatinine clearance ≥ 40 mL/min&#xD;
&#xD;
          -  Bilirubin ≤ 3 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST ≤ 3 times ULN&#xD;
&#xD;
          -  DLCO ≥ 40% with no symptomatic pulmonary disease&#xD;
&#xD;
          -  LVEF ≥ 30% by cardiac MRI or echocardiogram with no symptomatic cardiac disease&#xD;
&#xD;
          -  Fertile patients willing to use effective contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus&#xD;
&#xD;
          -  Active serious infection&#xD;
&#xD;
          -  Known hypersensitivity to E. coli-derived products&#xD;
&#xD;
          -  Known HIV positivity&#xD;
&#xD;
          -  History of another malignancy*, meeting the following criteria:&#xD;
&#xD;
               -  Non-skin malignancy or melanoma within the past 5 years&#xD;
&#xD;
               -  Concomitant malignancy that has not been curatively treated&#xD;
&#xD;
               -  NOTE: *However, cancer survivors who have undergone potentially curative therapy&#xD;
                  for a prior malignancy at least 5 years before enrollment and are deemed at low&#xD;
                  risk of &lt; 30% for recurrence by their treating physicians is considered&#xD;
&#xD;
          -  Pregnant or nursing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Hurd, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest University Comprehensive Cancer Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>March 27, 2007</study_first_submitted>
  <study_first_submitted_qc>March 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2007</study_first_posted>
  <results_first_submitted>May 28, 2014</results_first_submitted>
  <results_first_submitted_qc>June 30, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 2, 2014</results_first_posted>
  <last_update_submitted>August 7, 2018</last_update_submitted>
  <last_update_submitted_qc>August 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>primary myelofibrosis</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
  <keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II mantle cell lymphoma</keyword>
  <keyword>noncontiguous stage II marginal zone lymphoma</keyword>
  <keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>prolymphocytic leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III adult Burkitt lymphoma</keyword>
  <keyword>stage III adult Hodgkin lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage III adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III adult lymphoblastic lymphoma</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage III marginal zone lymphoma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>stage IV adult Hodgkin lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>polycythemia vera</keyword>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
  <keyword>stage I childhood Hodgkin lymphoma</keyword>
  <keyword>stage II childhood Hodgkin lymphoma</keyword>
  <keyword>stage III childhood Hodgkin lymphoma</keyword>
  <keyword>stage IV childhood Hodgkin lymphoma</keyword>
  <keyword>recurrent childhood anaplastic large cell lymphoma</keyword>
  <keyword>stage I childhood anaplastic large cell lymphoma</keyword>
  <keyword>stage II childhood anaplastic large cell lymphoma</keyword>
  <keyword>stage III childhood anaplastic large cell lymphoma</keyword>
  <keyword>stage IV childhood anaplastic large cell lymphoma</keyword>
  <keyword>recurrent childhood grade III lymphomatoid granulomatosis</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>stage I childhood large cell lymphoma</keyword>
  <keyword>stage II childhood large cell lymphoma</keyword>
  <keyword>stage III childhood large cell lymphoma</keyword>
  <keyword>stage IV childhood large cell lymphoma</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>stage I childhood lymphoblastic lymphoma</keyword>
  <keyword>stage II childhood lymphoblastic lymphoma</keyword>
  <keyword>stage III childhood lymphoblastic lymphoma</keyword>
  <keyword>stage IV childhood lymphoblastic lymphoma</keyword>
  <keyword>childhood nasal type extranodal NK/T-cell lymphoma</keyword>
  <keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
  <keyword>stage I childhood small noncleaved cell lymphoma</keyword>
  <keyword>stage II childhood small noncleaved cell lymphoma</keyword>
  <keyword>stage III childhood small noncleaved cell lymphoma</keyword>
  <keyword>stage IV childhood small noncleaved cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Reduced Intensity Allogeneic Cell Transplantation</title>
          <description>reduced intensisty transplant are those that do not completely eliminate the patient's stem cells prior to recieving the bone marrow transplant</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Reduced Intensity Allogeneic Cell Transplantation</title>
          <description>reduced intensisty transplant are those that do not completely eliminate the patient's stem cells prior to recieving the bone marrow transplant</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="66"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.1" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Treatment-related Mortality Within the First 6 Months After Transplantation</title>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Reduced Intensity Allogeneic Cell Transplantation</title>
            <description>reduced intensisty transplant are those that do not completely eliminate the patient's stem cells prior to recieving the bone marrow transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-related Mortality Within the First 6 Months After Transplantation</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complete Response</title>
        <time_frame>monthly</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <time_frame>monthly</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease-free Survival</title>
        <time_frame>monthly</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Graft-versus-host Disease</title>
        <time_frame>monthly</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Iron Status at the Time of Transplantation</title>
        <time_frame>baseline</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life at the Time of Transplantation</title>
        <time_frame>baseline</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment-related Mortality at 100 Days After Transplantation</title>
        <time_frame>100 days</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The only adverse events collected and analyzed for this study were grade 5 (death) related to transplant occurring within 6 months of transplant. No data was collected for less serious adverse events.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Reduced Intensity Allogeneic Cell Transplantation</title>
          <description>reduced intensisty transplant are those that do not completely eliminate the patient's stem cells prior to recieving the bone marrow transplant</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death of unknown cause</sub_title>
                <description>Cause of death could not be determined. Per study, this was considered related to transplant</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Graft versus host disease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Post transplant proliferative disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurological unspecified</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>By the time the primary objective of this trial was completed, the treatment approach of the trial had become standard of care. Analysis was therefore limited.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>David Hurd, MD</name_or_title>
      <organization>Wake Forest University Health Sciences</organization>
      <phone>336-716-2843</phone>
      <email>dhurd@wakehealth.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

